GlassScriptPhysician profile
Eric Krysiak
NPI 1609307263
$5,861.90
in general payments reported to CMS, 2019-2025
19 companies · $761 in 2025
The $761 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $125 · 2021: $471 · 2022: $1,835 · 2023: $1,505 · 2024: $1,047 · 2025: $761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,312.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $909.27 | 2022-2024 | Uzedy, Austedo Xr |
| Novo Nordisk INC | $801.25 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Janssen Pharmaceuticals, INC | $788.90 | 2022-2024 | Xarelto, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $615.25 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $482.98 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Inari Medical, INC. | $385.22 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boston Scientific Corporation | $261.44 | 2022-2024 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $250.10 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $243.47 | 2019-2021 | |
| Axsome Therapeutics, INC. | $228.73 | 2024 | Auvelity |
| Abbvie INC. | $147.85 | 2023 | |
| Novartis Pharmaceuticals Corporation | $138.27 | 2022-2024 | |
| Insulet Corporation | $124.99 | 2023 | Omnipod |
| E.R. Squibb & Sons, L.L.C. | $121.84 | 2025 | Cobenfy |
| Esperion Therapeutics, INC. | $117.80 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $103.57 | 2021 | |
| Ascendis Pharma Endocrinology INC | $86.43 | 2023 | |
| Janssen Scientific Affairs, LLC | $34.75 | 2024 | Xarelto |
| Paratek Pharmaceuticals, INC. | $19.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Krysiak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.